Tang Luo Ning, a Traditional Chinese Compound Prescription, Ameliorates Schwannopathy of Diabetic Peripheral Neuropathy Rats by Regulating Mitochondrial Dynamics In Vivo and In Vitro

Tang Luo Ning (TLN), a traditional Chinese compound prescription, has been used clinically to treat diabetic peripheral neuropathy (DPN) in China. However, the exact mechanisms remain unclear. The objective of this study is to unravel the effects of TLN on mitochondrial dynamics of DPN in streptozotocin-induced rat models and Schwann cells cultured in 150 mM glucose. Mitochondrial function was determined by Ca 2+ and ATP levels of streptozotocin (STZ)-induced DPN rats and mitochondria structure, mitochondrial membrane potential (MMP), and mtDNA of high glucose incubated SCs. Mitochondrial dynamics protein including mitofusin 1 (Mfn1), mitofusin 2 (Mfn2), optic atrophy 1 (Opa1), and dynamin-related protein 1 (Drp1) were investigated using Western blot or immunofluorescence. Myelin basic protein (MBP), myelin protein zero (MPZ), and sex-determining region Y (SRY)-box 10 (Sox10) were measured to represent schwannopathy. Our results showed that TLN increased ATP levels (0.38 of model, 0.69 of HTLN, 0.61 of LTLN, P ＜0.01; 0.52 of 150 mM glucose, 1.00 of 10% TLN, P ＜0.01, 0.94 of 1% TLN, P ＜0.05), MMP (0.56 of 150 mM glucose, P ＜0.01, 0.75 of 10% TLN, P ＜0.05, 0.83 of 1% TLN, P ＜0.01), and mtDNA (0.32 of 150 mM glucose, 0.43 of 10% TLN, P ＜0.01) while decreased Ca 2+ (1.54 of model, 1.06 of HTLN, 0.96 of LTLN, P ＜0.01) to improve mitochondrial function in vivo and in vitro . TLN helps maintain balance of mitochondrial dynamics: it reduces the mitochondria number (1.60 of 150 mM glucose, 1.10 of 10% TLN, P ＜0.01) and increases the mitochondria coverage (0.51 of 150 mM glucose, 0.80 of 10% TLN, 0.87 of 1% TLN, P ＜0.01), mitochondrial network size (0.51 of 150 mM glucose, 0.95 of 10% TLN, 0.94 of 1% TLN, P ＜0.01), and branch length (0.63 of 150 mM glucose, P ＜0.01, 0.73 of 10% TLN, P ＜0.05, 0.78 of 1% TLN, P ＜0.01). Further, mitochondrial dynamics–related Mfn1 (0.47 of model, 0.82 of HTLN, 0.77 of LTLN, P ＜0.01; 0.42 of 150 mM glucose, 0.56 of 10% TLN, 0.57 of 1% TLN, P ＜0.01), Mfn2 (0.40 of model, 0.84 of HTLN, 0.63 of LTLN, P ＜0.01; 0.46 of 150 mM glucose, 1.40 of 10% TLN, 1.40 of 1% TLN, P ＜0.01), and Opa1 (0.58 of model, 0.71 of HTLN, 0.90 of LTLN, P ＜0.01; 0.69 of 150 mM glucose, 0.96 of 10% TLN, 0.98 of 1% TLN, P ＜0.05) were increased, while Drp1 (1.39 of model, 0.96 of HTLN, 1.18 of LTLN, P ＜0.01; 1.70 of 150 mM glucose, 1.20 of 10% TLN, 1.10 of 1% TLN, P ＜0.05), phosphorylated Drp1 (2.61 of model, 1.44 of HTLN, P ＜0.05; 2.80 of 150 mM glucose, 1.50 of 10% TLN, 1.30 of 1% TLN, P ＜0.01), and Drp1 located in mitochondria (1.80 of 150 mM glucose, 1.00 of 10% TLN, P ＜0.05) were decreased after treatment with TLN. Additionally, TLN improved schwannopathy by increasing MBP (0.50 of model, 1.05 of HTLN, 0.94 of HTLN, P ＜0.01; 0.60 of 150 mM glucose, 0.78 of 10% TLN, P ＜0.01, 0.72 of 1% TLN, P ＜0.05), Sox101 (0.41 of model, 0.99 of LTLN, P ＜0.01; 0.48 of 150 mM glucose, 0.65 of 10% TLN, P ＜0.05, 0.69 of 1% TLN, P ＜0.01), and MPZ (0.48 of model, 0.66 of HTLN, 0.55 of HTLN, P ＜0.01; 0.60 of 150 mM glucose, 0.78 of 10% TLN, P ＜0.01, 0.75 of 1% TLN, P ＜0.05) expressions. In conclusion, our study indicated that TLN’s function on DPN may link to the improvement of the mitochondrial dynamics, which provides scientific evidence for the clinical application.